ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors
ONWARD Medical (OTCQX: ONWRY), a neurotechnology company focused on restoring movement and function in people with spinal cord injury, has appointed Lucas Buchanan as a non-executive member of its Board of Directors. Buchanan brings over 25 years of expertise in commercialization, operations, and finance.
As former CFO and COO of Silk Road Medical, Buchanan led the company from founding through its IPO in 2019 and subsequent acquisition by Boston Scientific in 2024. His experience includes roles at The Vertical Group, Impax Laboratories, Warburg Pincus, and Medtronic. He currently serves on several medical technology company boards and holds degrees from Duke University and The Wharton School.
ONWARD Medical (OTCQX: ONWRY), un'azienda di neurotecnologia specializzata nel ripristino del movimento e delle funzioni nelle persone con lesioni del midollo spinale, ha nominato Lucas Buchanan come membro non esecutivo del suo Consiglio di Amministrazione. Buchanan vanta oltre 25 anni di esperienza in commercializzazione, operazioni e finanza.
In qualit脿 di ex CFO e COO di Silk Road Medical, Buchanan ha guidato la societ脿 dalla sua fondazione fino all'IPO nel 2019 e alla successiva acquisizione da parte di Boston Scientific nel 2024. La sua esperienza comprende ruoli presso The Vertical Group, Impax Laboratories, Warburg Pincus e Medtronic. Attualmente siede in diversi consigli di amministrazione di aziende nel settore della tecnologia medica e possiede titoli di studio conseguiti presso la Duke University e la Wharton School.
ONWARD Medical (OTCQX: ONWRY), una empresa de neurotecnolog铆a enfocada en restaurar el movimiento y la funci贸n en personas con lesiones de la m茅dula espinal, ha nombrado a Lucas Buchanan como miembro no ejecutivo de su Junta Directiva. Buchanan aporta m谩s de 25 a帽os de experiencia en comercializaci贸n, operaciones y finanzas.
Como ex CFO y COO de Silk Road Medical, Buchanan lider贸 la compa帽铆a desde su fundaci贸n hasta su oferta p煤blica inicial en 2019 y la posterior adquisici贸n por Boston Scientific en 2024. Su experiencia incluye roles en The Vertical Group, Impax Laboratories, Warburg Pincus y Medtronic. Actualmente forma parte de varias juntas directivas de empresas de tecnolog铆a m茅dica y posee t铆tulos de la Universidad Duke y de The Wharton School.
ONWARD Medical (OTCQX: ONWRY)電� 觳欖垬 靻愳儊 頇橃瀽鞚� 鞗�歆侅瀯瓿� 旮半姤 須岆车鞐� 欤茧牓頃橂姅 鞁犼步旮办垹 須岇偓搿�, 耄勾鞀� 攵�旌愲剬(Lucas Buchanan)鞚� 牍勳儊鞛� 鞚挫偓搿� 鞛勲獏頄堨姷雼堧嫟. 攵赌旌愲剬鞚赌 靸侅梾頇�, 鞖挫榿 氚� 鞛 攵勳暭鞐愳劀 25雲� 鞚挫儊鞚� 瓴巾棙鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
攵赌旌愲剬鞚赌 Silk Road Medical鞚� 鞝� CFO 氚� COO搿滌劀, 2019雲� 旮办梾瓿店皽(IPO)攵�韯� 2024雲� 氤挫姢韯� 靷澊鞏疙嫲頂届棎 鞚胳垬霅� 霑岅箤歆� 須岇偓毳� 鞚措亴鞐堨姷雼堧嫟. 攴胳潣 瓴诫牓鞐愲姅 The Vertical Group, Impax Laboratories, Warburg Pincus, Medtronic鞐愳劀鞚� 鞐暊鞚� 韽暔霅╇媹雼�. 順勳灛 鞐煬 鞚橂旮办垹 須岇偓鞚� 鞚挫偓須岇棎 彀胳棳頃橁碃 鞛堨溂氅� 霌�韥� 雽�頃欔祼鞕� 鞕�韸� 鞀れ卡鞐愳劀 頃欖渼毳� 氚涭晿鞀惦媹雼�.
ONWARD Medical (OTCQX : ONWRY), une entreprise de neurotechnologie sp茅cialis茅e dans la restauration du mouvement et des fonctions chez les personnes atteintes de l茅sions de la moelle 茅pini猫re, a nomm茅 Lucas Buchanan membre non ex茅cutif de son conseil d'administration. Buchanan apporte plus de 25 ans d'expertise en commercialisation, op茅rations et finance.
Ancien CFO et COO de Silk Road Medical, Buchanan a dirig茅 l'entreprise depuis sa cr茅ation jusqu'脿 son introduction en bourse en 2019, puis sa rachat par Boston Scientific en 2024. Son exp茅rience inclut des postes chez The Vertical Group, Impax Laboratories, Warburg Pincus et Medtronic. Il si猫ge actuellement dans plusieurs conseils d'administration d'entreprises de technologie m茅dicale et est dipl么m茅 de l'universit茅 Duke et de la Wharton School.
ONWARD Medical (OTCQX: ONWRY), ein Neurotechnologieunternehmen, das sich auf die Wiederherstellung von Bewegung und Funktion bei Menschen mit R眉ckenmarksverletzungen spezialisiert hat, hat Lucas Buchanan als nicht-exekutives Mitglied in seinen Vorstand berufen. Buchanan bringt 眉ber 25 Jahre Erfahrung in den Bereichen Kommerzialisierung, Betrieb und Finanzen mit.
Als ehemaliger CFO und COO von Silk Road Medical f眉hrte Buchanan das Unternehmen von der Gr眉ndung bis zum B枚rsengang 2019 und der anschlie脽enden 脺bernahme durch Boston Scientific im Jahr 2024. Seine Erfahrung umfasst Positionen bei The Vertical Group, Impax Laboratories, Warburg Pincus und Medtronic. Derzeit ist er in mehreren Vorst盲nden von Medizintechnikunternehmen t盲tig und hat Abschl眉sse von der Duke University und der Wharton School.
- Appointment of seasoned executive with successful track record of scaling and exiting medical device companies
- Addition of board member with extensive NASDAQ listing and IPO experience
- Strategic expertise in commercialization and operations from leadership roles at major healthcare companies
- None.
- Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific.
- Buchanan, formerly a venture capitalist with the Vertical Group, is also an active investor, advisor, and board member for several innovative medical device companies and healthcare investment funds.
EINDHOVEN, The Netherlands, Aug. 06, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces the appointment of Lucas Buchanan as a non-executive member of its Board of Directors.
鈥淲e are delighted to welcome Lucas Buchanan to our Board of Directors,鈥� said Dave Marver, CEO of ONWARD Medical. 鈥淟ucas has a unique and valuable set of experiences as an operator, investor, and leader. He has also successfully NASDAQ-listed, scaled, and exited a medical technology company. He is ideally qualified to join our Board as we grow our business and pursue our mission.鈥�
鈥淥NWARD is a truly unique company powered by an inspiring vision and breathtaking technology. The Company is delivering hope to people with spinal cord injury and other movement disabilities,鈥� said Buchanan. 鈥淚 look forward to helping Dave and the team pursue its ambitions for the benefit of millions of people around the globe.鈥�
Buchanan brings over 25 years of expertise聽in commercialization, operations, business development, investing, and finance. As the Chief Operating Officer and Chief Financial Officer at Silk Road Medical, he helped lead the company from its founding through to its IPO in 2019 and ultimate sale to Boston Scientific in 2024. Buchanan previously held roles at The Vertical Group, Impax Laboratories, Warburg Pincus, Medtronic, and Ernst & Young.
Buchanan is an active investor who currently serves on the聽Boards聽of Directors for several medical technology companies, including Element Science, Aerin Medical, Route 92 Medical, Procyrion, and Endologix. He holds a BA in Economics from Duke University and an MBA in Health Care Management from The Wharton School at the University of Pennsylvania.
About ONWARD Medical
ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company鈥檚 ARC-EX System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI).
Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY).
To learn more about ONWARD Medical鈥檚 commitment to partnering with the spinal cord injury community to develop innovative solutions for restoring movement, function, and independence, please visit .
To be kept informed about the Company鈥檚 technologies, research studies, and the availability of therapies in your area, please .
For Media Inquiries:
S茅bastien Cros, VP Communications
For Investor Inquiries:
Disclaimer
Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company鈥檚 or, as appropriate, the Company directors鈥� current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person鈥檚 officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
FAQ
Who is Lucas Buchanan and what is his role at ONWARD Medical (ONWRY)?
What experience does Lucas Buchanan bring to ONWARD Medical's board?
What was Lucas Buchanan's role in Silk Road Medical's exit to Boston Scientific?
What other board positions does Lucas Buchanan currently hold?
